Table 1.
Baseline characteristics of patients with de novo la/mUC.
| Variable | De Novo Cohort (N = 206) | |
|---|---|---|
| Age | Mean (SD), years | 73.0 (10.1) |
| <60 years, n (%) | 45 (21.8) | |
| ≥60 years, n (%) | 161 (78.2) | |
| Sex, n (%) | Female | 43 (20.9) |
| Male | 163 (79.1) | |
| Year of diagnosis, n (%) [median follow-up, months] |
2015 | 32 (15.5) [4.0] |
| 2016 | 31 (15.0) [6.0] | |
| 2017 | 43 (20.9) [4.4] | |
| 2018 | 33 (16.0) [4.6] | |
| 2019 | 67 (32.5) [5.9] | |
| AJCC TNM stage at diagnosis, n (%) | Unresected locally advanced | 40 (19.4) |
| Metastatic UC | 166 (80.6) | |
| Disease histology, n (%) | TCC | 206 (100) |
| No. of metastasis sites at diagnosis, n (%) | 0 | 40 (19.4) |
| 1 | 96 (46.6) | |
| 2 | 45 (21.8) | |
| ≥3 | 24 (11.7) | |
| Missing | 1 (0.5) | |
| Sites of metastases at diagnosis a, n (%) | Lymph nodes | 83 (40.5) |
| Bone | 55 (26.8) | |
| Lung | 44 (21.5) | |
| Hepatic | 36 (17.6) | |
| Peritoneum | 20 (9.8) | |
| Adrenals | <10 | |
| Brain | <10 | |
| Other | 18 (8.8) | |
a One patient was excluded from the analyses due to missing data on metastasis sites; patients may have more than one metastasis in more than one site. Abbreviations: AJCC, American Joint Committee on Cancer; TCC, transitional cell carcinoma; TNM, tumor node metastasis; UC, urothelial carcinoma.